S318 Optimized Lower Dose Combinations of Sulindac Plus Erlotinib Sustained Antitumor Efficacy and Reduced Toxicity in a Preclinical Model of FAP. (October 2021) - Demirhan, Yunus Emre; Rajendran, Praveen; Dashwood, Wan-Mohaiza; Kapoor, Sabeeta; Ulusan, Ahmet; Tripathi, Chakrapani; Demirhan, Melek; Shapiro, Alessandro; Savage, Michelle; Brown, Powel; Sei, Shizuko; Mohammed, Altaf; et al.